These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 9493121

  • 1. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS.
    J Hypertens Suppl; 1997 Dec; 15(6):S9-12. PubMed ID: 9493121
    [Abstract] [Full Text] [Related]

  • 2. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.
    McInnes GT, O'Kane KP, Istad H, Keinänen-Kiukaanniemi S, Van Mierlo HF.
    J Hum Hypertens; 2000 Apr; 14(4):263-9. PubMed ID: 10805052
    [Abstract] [Full Text] [Related]

  • 4. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
    Melian EB, Jarvis B.
    Drugs; 2002 Apr; 62(5):787-816. PubMed ID: 11929332
    [Abstract] [Full Text] [Related]

  • 5. Candesartan cilexetil. A review of its use in essential hypertension.
    McClellan KJ, Goa KL.
    Drugs; 1998 Nov; 56(5):847-69. PubMed ID: 9829158
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H, Ogihara T, Miyata Y, Sasai K, Totsuka N.
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [Abstract] [Full Text] [Related]

  • 7. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.
    Oparil S, Levine JH, Zuschke CA, Gradman AH, Ripley E, Jones DW, Hardison JD, Cushing DJ, Prasad R, Michelson EL.
    Am J Cardiol; 1999 Aug 01; 84(3):289-93. PubMed ID: 10496437
    [Abstract] [Full Text] [Related]

  • 8. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.
    Reif M, White WB, Fagan TC, Oparil S, Flanagan TL, Edwards DT, Cushing DJ, Michelson EL.
    Am J Cardiol; 1998 Oct 15; 82(8):961-5. PubMed ID: 9794352
    [Abstract] [Full Text] [Related]

  • 9. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
    Ogihara T, Arakawa K.
    J Hum Hypertens; 1999 Jan 15; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
    [Abstract] [Full Text] [Related]

  • 10. Candesartan cilexetil: an update of its use in essential hypertension.
    Easthope SE, Jarvis B.
    Drugs; 2002 Jan 15; 62(8):1253-87. PubMed ID: 12010090
    [Abstract] [Full Text] [Related]

  • 11. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
    Himmelmann A, Keinänen-Kiukaanniemi S, Wester A, Redón J, Asmar R, Hedner T, Effect Study Group.
    Blood Press; 2001 Jan 15; 10(1):43-51. PubMed ID: 11332334
    [Abstract] [Full Text] [Related]

  • 12. Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.
    Oparil S.
    Am J Cardiol; 1999 Nov 18; 84(10A):35S-41S. PubMed ID: 10588093
    [Abstract] [Full Text] [Related]

  • 13. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S, Stirling AL.
    Am J Health Syst Pharm; 2000 Apr 15; 57(8):739-46. PubMed ID: 10786259
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K, Kahan T, Dahl M.
    Am J Hypertens; 2000 May 15; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [Abstract] [Full Text] [Related]

  • 15. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
    Andersson OK, Neldam S.
    Blood Press; 1998 Jan 15; 7(1):53-9. PubMed ID: 9551878
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide.
    Ohma KP, Milon H, Valnes K.
    Blood Press; 2000 Jan 15; 9(4):214-20. PubMed ID: 11055474
    [Abstract] [Full Text] [Related]

  • 17. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA, McVoy HJ, Kaul AF.
    Ann Pharmacother; 1999 Dec 15; 33(12):1287-98. PubMed ID: 10630830
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.